Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines.

"Competing interests K.P.W. is an advisor and shareholder in Tempus Labs, Inc. and a director and shareholder in Provaxus, Inc. and its subsidiaries. A.L. is a shareholder in Provaxus, Inc. and its subsidiaries. P.A.M., B.S., R.G., and G.Y. are co-inventors of the surrogate viral neutralisation test used in this study, which has been commercialized as the ImTracker COVID-19 viral variant neutralisation test (GENY BIOLOGICS, https://genybiologics.com/imtracker/)."

"This study was financially supported by the Bioprocessing Technology Institute (BTI), Genome Institute of Singapore (GIS) and a Use Inspired Basic Research (UIBR) grant from, A*STAR, Republic of Singapore. This study was also funded by Provaxus, Inc. and the National University of Singapore."